44
Participants
Start Date
December 1, 2026
Primary Completion Date
June 30, 2030
Study Completion Date
June 30, 2030
Erlotinib
Part B will be the dose escalation component, in which the subject will initiate 50 mg erlotinib,8 weeks later escalate to 75 mg, and then 8 weeks later to 100 mg erlotinib pending tolerance after each 8-week period.
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago
Yale University
OTHER
Northwestern University
OTHER